Gallant Reports Positive Pilot Data for Feline Osteoarthritis Stem Cell Therapy; Receives FDA Eligibility for Expanded Conditional Approval Pathway

Key Points

• Gallant reported positive pilot data for its intravenous uterine-derived mesenchymal stromal cell (UMSC) therapy in cats with osteoarthritis, with treated cats showing better pain and quality-of-life outcomes than placebo.
• The FDA Center for Veterinary Medicine granted the program eligibility for the expanded conditional approval pathway, which could shorten the route to market while effectiveness is still being confirmed.
• The randomized, placebo-controlled study enrolled 35 cats across six U.S. veterinary clinics, and a one-year continuation study of the low-dose regimen is ongoing.

Pilot study results

Gallant has reported positive pilot data for its feline osteoarthritis program and said the findings support further development of an intravenous stem cell therapy for cats with naturally occurring disease. The therapy uses uterine-derived mesenchymal stromal cells (UMSCs), a type of mesenchymal stem cell (MSC), delivered in two IV doses given 14 days apart.

The study was randomized, masked, and placebo-controlled. It enrolled 35 client-owned cats with radiographically confirmed osteoarthritis at six U.S. veterinary clinics. Cats received either a low dose of 5 million cells, a high dose of 20 million cells, or a saline placebo, and were followed for 90 days with assessments from both veterinarians and cat owners.

Gallant said the therapy was well-tolerated and produced statistically significant, clinically relevant improvement across owner-reported and veterinarian-assessed measures.

• Client-specific outcome measure (CSOM): 76.2% of treated cats improved vs. 36.4% of placebo
• Owner-assessed overall quality of life: 81% of treated cats improved vs. 36.4% of placebo
• Veterinarian-assessed pain scores: 81% of treated cats improved vs. 45.5% of placebo
• Veterinarian-assessed overall quality of life: 60% of treated cats improved vs. 20% of placebo

Regulatory pathway and disease context

Gallant also said the FDA Center for Veterinary Medicine determined the feline osteoarthritis therapy is eligible for the expanded conditional approval pathway. This pathway is intended for products addressing a significant unmet medical need and can enable commercialization based on target-animal safety and cGMP-quality manufacturing while full effectiveness data are still being collected.

Osteoarthritis is common in older cats and is associated with pain, reduced mobility, and declines in daily function and well-being. Gallant argues that currently marketed drugs mainly address symptoms, while MSC-based therapies may have immunomodulatory effects that could target underlying disease processes. That disease-modifying potential remains investigational.

The 90-day study results have been submitted for publication, and the company’s continuation study is ongoing to evaluate the safety and efficacy of the low-dose therapy out to one year.

Company comments and pipeline

“This data marks additional meaningful progress toward a new category of care, where regenerative medicine targets disease at its source,” said Dr. Linda Black, DVM, Ph.D., CEO of Gallant. “Osteoarthritis remains a significant burden for cats and their families, and current treatments largely manage symptoms rather than addressing the underlying joint pathology. As we continue to study duration of effect for feline OA, we’re encouraged about the potential to deliver long-lasting relief – particularly given results from our refractory feline chronic gingivostomatitis program, where two-thirds of cats showed a positive response one year post-treatment.”

Gallant said its broader pipeline is focused heavily on feline medicine, an area that has historically had fewer therapeutic options than other veterinary segments.

“Felines have long been overlooked in medical research and therapeutic development, leaving a significant gap in care for a population that deserves far more attention,” said Dr. Rebecca Windsor, vice president of Veterinary Affairs at Gallant. “Our mission at Gallant is to change that. By advancing cutting-edge regenerative therapies specifically for cats, we aim to lead a new era of innovation that brings meaningful, feline-specific solutions to this underserved community.”

Gallant’s pipeline also includes programs in canine osteoarthritis, feline chronic kidney disease, canine atopic dermatitis, and refractory feline chronic gingivostomatitis, with the latter expected to reach a conditional approval decision later this year.

Want to keep up on regenerative medicine? Get the weekly newsletter here.